Bayesian Capital Management, LP Recursion Pharmaceuticals, Inc. Transaction History

Bayesian Capital Management, LP

  • $838 Million
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$7.35 - $10.05 $311,640 - $426,120
42,400 New
42,400 $318,000
Q3 2023

Nov 14, 2023
BUY
$6.59 - $15.86 $392,836 - $945,430
59,611 New
59,611 $456,000
Q1 2023

May 15, 2023
SELL
$6.42 - $9.64 $239,466 - $359,572
-37,300 Reduced 60.75%
24,095 $160,000
Q4 2022

Feb 14, 2023
BUY
$7.16 - $12.7 $439,588 - $779,716
61,395 New
61,395 $473,000
Q2 2022

Aug 15, 2022
SELL
$5.04 - $9.26 $129,528 - $237,982
-25,700 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$6.16 - $18.03 $158,312 - $463,371
25,700 New
25,700 $184,000

Others Institutions Holding RXRX

# of Institutions
286
Shares Held
242M
Call Options Held
1.35M
Put Options Held
2.32M
View Full List

About RECURSION PHARMACEUTICALS, INC.

RXRX Quotes by TradingView
  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.12B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email